Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 10/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23269644 | 0.82 | L3MBTL1 (0.40) | ALDH1A1SMN1; SMN2KDM4EPKMKMT2A | |
| SCHEMBL22102443 | 0.81 | CACNA2D1 (0.34) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL24204398 | 0.80 | NCF1 (0.41) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL5659414 | 0.80 | ALDH1A1 (0.41) | ALDH1A1NCF1KDM4ECYP3A4PKM | |
| SCHEMBL24236669 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CCR2NCF1SMN1; SMN2KDM1A | |
| SCHEMBL20231639 | 0.79 | MAPK1 (0.36) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL19977427 | 0.79 | MAPK1 (0.36) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL23407913 | 0.78 | CCR2 (0.32) | ALDH1A1CCR2SMN1; SMN2KCNH2KDM1A | |
| SCHEMBL16803624 | 0.77 | ALDH1A1 (0.38) | ALDH1A1NCF1SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL24398849 | 0.77 | GNAO1 (0.34) | CACNA2D1CACNA1BCACNB1CACNA1CCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | CAMK1, CAMKK2, DCLK2 | ALDH1A1 4117/4885CACNA2D1 1886/4885CACNA1B 1706/4885 |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | CAMK1, CAMKK2, DCLK2 | ALDH1A1 4117/4885CACNA2D1 1886/4885CACNA1B 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.